CytoDyn
Biotechnology
Overview
CytoDyn is a biotechnology company focused on developing innovative treatments for multiple therapeutic indications based on Leronlimab (PRO 140).
Key facts
These are the key facts about CytoDyn on Alion as of Nov 13, 2026. CytoDyn is headquartered in Vancouver, United States. It has raised $143M in 13 funding rounds. The latest round is Venture - Series Unknown of $18.6M, announced in 2026.
- Headquarters
- Vancouver, United StatesAlion company profile, updated Nov 8, 2026
- Total raised
- $143MSum of 13 equity rounds Alion knows
- Latest round
- Venture - Series Unknown · $18.6M · Jan 30, 2026SEC Form D filing · sec.gov
Official records
Funding and backers
Total raised
$143M
14 rounds on record
Latest round
$18.6M
Venture round · Jan 2026 · 9 mo ago
The money's age
Fresh money
9 months since the last round · not hiring
Momentum
20/100
fresh money
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Jan 30
Raised a round Venture round $18.6M · SEC Form D
Apr 7, 2022
Raised a round Venture round $21.8M · SEC Form D
Nov 17, 2021
Raised a round Venture round $11.4M · SEC Form D
Aug 31, 2021
Raised a round Venture round $2.9M · SEC Form D
Nov 7, 2020
Raised a round Venture round $1M · SEC Form D
Mar 13, 2020
Raised a round Venture round $882k · SEC Form D
Jan 31, 2020
Raised a round Venture round $7.6M · SEC Form D
Mar 20, 2019
Raised a round Venture round $7.8M · SEC Form D
Aug 28, 2018
Raised a round Venture round $13.2M · SEC Form D
Nov 2, 2017
Raised a round Venture round $17.6M · SEC Form D
May 31, 2017
Took on debt financing $1.2M · SEC Form D
Apr 26, 2016
Raised a round Venture round $4.3M · SEC Form D
Sep 21, 2015
Raised a round Venture round $2.7M · SEC Form D
Jun 30, 2015
Raised a round Venture round $33.3M · SEC Form D
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Venture round | Jan 2026 | $18.6M | — | SEC Form D |
| Venture round | Apr 2022 | $21.8M | — | SEC Form D |
| Venture round | Nov 2021 | $11.4M | — | SEC Form D |
| Venture round | Aug 2021 | $2.9M | — | SEC Form D |
| Venture round | Nov 2020 | $1M | — | SEC Form D |
| Venture round | Mar 2020 | $882k | — | SEC Form D |
| Venture round | Jan 2020 | $7.6M | — | SEC Form D |
| Venture round | Mar 2019 | $7.8M | — | SEC Form D |
| Venture round | Aug 2018 | $13.2M | — | SEC Form D |
| Venture round | Nov 2017 | $17.6M | — | SEC Form D |
| Debt Financing | May 2017 | $1.2M | — | SEC Form D |
| Venture round | Apr 2016 | $4.3M | — | SEC Form D |
| Venture round | Sep 2015 | $2.7M | — | SEC Form D |
| Venture round | Jun 2015 | $33.3M | — | SEC Form D |
Registers and programsofficial lists and records that name the company
| Legal entity | CytoDyn Inc. | SEC Form D |
Founders and leadersfrom filings, registers and the company's site
Jacob LalezariExecutive OfficerSEC Form D
Robert HoffmanExecutive OfficerSEC Form D
Tyler BlokExecutive OfficerSEC Form D
Investors in similar startupsfunds that back the companies most like this one
Similar startupsby what they do, their industry and backers
光粒，光粒科技，AR智能泳镜，智能泳镜，AR泳镜，泳镜，游泳镜，游泳眼镜，Holosport，holosport，Holoswim，holoswim，Holoswim2s，holoswim2s，Holoswim 2 Pro，holoswim 2 Pro，#更智能更健康.
星锐医药(Starna Therapeutics) 成立于2021年8月，公司聚焦肝外靶向递送技术，致力于研发以RNA为核心的创新药物，解决未被满足的临床需求。核心团队来自知名药企、高校和研究院所，团队拥有深厚的核酸药物发现、递送技术和制剂开发能力。.
Innovative Treatment for a Pipeline of Inflammatory Indications. CytoAgents is advancing CTO1681 for multiple indications where…
Who we are Innovation driven by profound experience Established in 2016 in Heidelberg (Germany), EXCIVA is a privately held biotech company…
Cadenza Bio is a preclinical biotechnology company focused on developing a series of novel small-molecule drugs for the treatment of…
We develop innovative antibody-based solutions to improve transfusion safety. Our platform enables clinical-grade applications across…
Financials
Total raised
$144.1M
Latest round
Venture - Series Unknown
Funding rounds
14
Funding rounds
| Round | Announced | Amount | |
|---|---|---|---|
| Venture - Series Unknown | 2026 | $18.6M | Details |
| Venture - Series Unknown | 2022 | $21.8M | Details |
| Venture - Series Unknown | 2021 | $11.4M | Details |
| Venture - Series Unknown | 2021 | $2.9M | Details |
| Venture - Series Unknown | 2020 | $1M | Details |
| Venture - Series Unknown | 2020 | $882k | Details |
| Venture - Series Unknown | 2020 | $7.6M | Details |
| Venture - Series Unknown | 2019 | $7.8M | Details |
| Venture - Series Unknown | 2018 | $13.2M | Details |
| Venture - Series Unknown | 2017 | $17.6M | Details |
| Debt Financing | 2017 | $1.2M | Details |
| Venture - Series Unknown | 2016 | $4.3M | Details |
| Venture - Series Unknown | 2015 | $2.7M | Details |
| Venture - Series Unknown | 2015 | $33.3M | Details |
People
Jacob Lalezari
Executive Officer
Robert Hoffman
Executive Officer
Tyler Blok
Executive Officer
Lishomwa Ndhlovu M.D. Ph.D.
Director
Karen Brunke Ph.D.
Director
Ryan Dunlap
Director
Tanya Urbach
Director
Stephen Simes
Director
Names and roles come from public filings, company registers and the company's own site. Is this you? Correct or remove · How we handle this data
Offices
Where the company hires and what each office is for
Cities
2
Hiring now
0
Countries
1
Loading the map
Headquarters
Builds here
Office with open vacancies
No open vacancies right now Tap a pin for the office
Vancouver
United States
HQ
Louisville
United States
Regional office
Stock Transfer Agent
P.O. Box 505002, Louisville, KY 40233-5002
How to cite this page
Alion, "CytoDyn: key facts", as of Nov 13, 2026. https://alion.io/company/cytodyn
These figures are published under a free licence. You may reuse them, including commercially, as long as you credit Alion and link back to this page. CC BY-SA 4.0